Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Glucagon Market

ID: MRFR/HC/28295-HCR
128 Pages
Rahul Gotadki
Last Updated: April 06, 2026

Glucagon Market Research Report By Indication (Hypoglycemia, Diabetic Ketoacidosis, Other Indications), By Route of Administration (Intravenous, Subcutaneous, Intramuscular), By Glucagon Origin (Human, Synthetic, Animal-derived), By Dosage Form (Injectable, Nasal Spray, Other Dosage Forms) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Glucagon Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Indication (USD Billion)
  49.     4.1.1 Hypoglycemia
  50.     4.1.2 Diabetic Ketoacidosis
  51.     4.1.3 Other Indications
  52.   4.2 Healthcare, BY Route of Administration (USD Billion)
  53.     4.2.1 Intravenous
  54.     4.2.2 Subcutaneous
  55.     4.2.3 Intramuscular
  56.   4.3 Healthcare, BY Glucagon Origin (USD Billion)
  57.     4.3.1 Human
  58.     4.3.2 Synthetic
  59.     4.3.3 Animal-derived
  60.   4.4 Healthcare, BY Dosage Form (USD Billion)
  61.     4.4.1 Injectable
  62.     4.4.2 Nasal Spray
  63.     4.4.3 Other Dosage Forms
  64.   4.5 Healthcare, BY Region (USD Billion)
  65.     4.5.1 North America
  66.       4.5.1.1 US
  67.       4.5.1.2 Canada
  68.     4.5.2 Europe
  69.       4.5.2.1 Germany
  70.       4.5.2.2 UK
  71.       4.5.2.3 France
  72.       4.5.2.4 Russia
  73.       4.5.2.5 Italy
  74.       4.5.2.6 Spain
  75.       4.5.2.7 Rest of Europe
  76.     4.5.3 APAC
  77.       4.5.3.1 China
  78.       4.5.3.2 India
  79.       4.5.3.3 Japan
  80.       4.5.3.4 South Korea
  81.       4.5.3.5 Malaysia
  82.       4.5.3.6 Thailand
  83.       4.5.3.7 Indonesia
  84.       4.5.3.8 Rest of APAC
  85.     4.5.4 South America
  86.       4.5.4.1 Brazil
  87.       4.5.4.2 Mexico
  88.       4.5.4.3 Argentina
  89.       4.5.4.4 Rest of South America
  90.     4.5.5 MEA
  91.       4.5.5.1 GCC Countries
  92.       4.5.5.2 South Africa
  93.       4.5.5.3 Rest of MEA
  94. 5 SECTION V: COMPETITIVE ANALYSIS
  95.   5.1 Competitive Landscape
  96.     5.1.1 Overview
  97.     5.1.2 Competitive Analysis
  98.     5.1.3 Market share Analysis
  99.     5.1.4 Major Growth Strategy in the Healthcare
  100.     5.1.5 Competitive Benchmarking
  101.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  102.     5.1.7 Key developments and growth strategies
  103.       5.1.7.1 New Product Launch/Service Deployment
  104.       5.1.7.2 Merger & Acquisitions
  105.       5.1.7.3 Joint Ventures
  106.     5.1.8 Major Players Financial Matrix
  107.       5.1.8.1 Sales and Operating Income
  108.       5.1.8.2 Major Players R&D Expenditure. 2023
  109.   5.2 Company Profiles
  110.     5.2.1 Novo Nordisk (DK)
  111.       5.2.1.1 Financial Overview
  112.       5.2.1.2 Products Offered
  113.       5.2.1.3 Key Developments
  114.       5.2.1.4 SWOT Analysis
  115.       5.2.1.5 Key Strategies
  116.     5.2.2 Sanofi (FR)
  117.       5.2.2.1 Financial Overview
  118.       5.2.2.2 Products Offered
  119.       5.2.2.3 Key Developments
  120.       5.2.2.4 SWOT Analysis
  121.       5.2.2.5 Key Strategies
  122.     5.2.3 Eli Lilly and Company (US)
  123.       5.2.3.1 Financial Overview
  124.       5.2.3.2 Products Offered
  125.       5.2.3.3 Key Developments
  126.       5.2.3.4 SWOT Analysis
  127.       5.2.3.5 Key Strategies
  128.     5.2.4 Boehringer Ingelheim (DE)
  129.       5.2.4.1 Financial Overview
  130.       5.2.4.2 Products Offered
  131.       5.2.4.3 Key Developments
  132.       5.2.4.4 SWOT Analysis
  133.       5.2.4.5 Key Strategies
  134.     5.2.5 Amgen (US)
  135.       5.2.5.1 Financial Overview
  136.       5.2.5.2 Products Offered
  137.       5.2.5.3 Key Developments
  138.       5.2.5.4 SWOT Analysis
  139.       5.2.5.5 Key Strategies
  140.     5.2.6 Pfizer (US)
  141.       5.2.6.1 Financial Overview
  142.       5.2.6.2 Products Offered
  143.       5.2.6.3 Key Developments
  144.       5.2.6.4 SWOT Analysis
  145.       5.2.6.5 Key Strategies
  146.     5.2.7 Bristol-Myers Squibb (US)
  147.       5.2.7.1 Financial Overview
  148.       5.2.7.2 Products Offered
  149.       5.2.7.3 Key Developments
  150.       5.2.7.4 SWOT Analysis
  151.       5.2.7.5 Key Strategies
  152.     5.2.8 Mylan (US)
  153.       5.2.8.1 Financial Overview
  154.       5.2.8.2 Products Offered
  155.       5.2.8.3 Key Developments
  156.       5.2.8.4 SWOT Analysis
  157.       5.2.8.5 Key Strategies
  158.   5.3 Appendix
  159.     5.3.1 References
  160.     5.3.2 Related Reports
  161. 6 LIST OF FIGURES
  162.   6.1 MARKET SYNOPSIS
  163.   6.2 NORTH AMERICA MARKET ANALYSIS
  164.   6.3 US MARKET ANALYSIS BY INDICATION
  165.   6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  166.   6.5 US MARKET ANALYSIS BY GLUCAGON ORIGIN
  167.   6.6 US MARKET ANALYSIS BY DOSAGE FORM
  168.   6.7 CANADA MARKET ANALYSIS BY INDICATION
  169.   6.8 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  170.   6.9 CANADA MARKET ANALYSIS BY GLUCAGON ORIGIN
  171.   6.10 CANADA MARKET ANALYSIS BY DOSAGE FORM
  172.   6.11 EUROPE MARKET ANALYSIS
  173.   6.12 GERMANY MARKET ANALYSIS BY INDICATION
  174.   6.13 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  175.   6.14 GERMANY MARKET ANALYSIS BY GLUCAGON ORIGIN
  176.   6.15 GERMANY MARKET ANALYSIS BY DOSAGE FORM
  177.   6.16 UK MARKET ANALYSIS BY INDICATION
  178.   6.17 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  179.   6.18 UK MARKET ANALYSIS BY GLUCAGON ORIGIN
  180.   6.19 UK MARKET ANALYSIS BY DOSAGE FORM
  181.   6.20 FRANCE MARKET ANALYSIS BY INDICATION
  182.   6.21 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  183.   6.22 FRANCE MARKET ANALYSIS BY GLUCAGON ORIGIN
  184.   6.23 FRANCE MARKET ANALYSIS BY DOSAGE FORM
  185.   6.24 RUSSIA MARKET ANALYSIS BY INDICATION
  186.   6.25 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  187.   6.26 RUSSIA MARKET ANALYSIS BY GLUCAGON ORIGIN
  188.   6.27 RUSSIA MARKET ANALYSIS BY DOSAGE FORM
  189.   6.28 ITALY MARKET ANALYSIS BY INDICATION
  190.   6.29 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  191.   6.30 ITALY MARKET ANALYSIS BY GLUCAGON ORIGIN
  192.   6.31 ITALY MARKET ANALYSIS BY DOSAGE FORM
  193.   6.32 SPAIN MARKET ANALYSIS BY INDICATION
  194.   6.33 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  195.   6.34 SPAIN MARKET ANALYSIS BY GLUCAGON ORIGIN
  196.   6.35 SPAIN MARKET ANALYSIS BY DOSAGE FORM
  197.   6.36 REST OF EUROPE MARKET ANALYSIS BY INDICATION
  198.   6.37 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  199.   6.38 REST OF EUROPE MARKET ANALYSIS BY GLUCAGON ORIGIN
  200.   6.39 REST OF EUROPE MARKET ANALYSIS BY DOSAGE FORM
  201.   6.40 APAC MARKET ANALYSIS
  202.   6.41 CHINA MARKET ANALYSIS BY INDICATION
  203.   6.42 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  204.   6.43 CHINA MARKET ANALYSIS BY GLUCAGON ORIGIN
  205.   6.44 CHINA MARKET ANALYSIS BY DOSAGE FORM
  206.   6.45 INDIA MARKET ANALYSIS BY INDICATION
  207.   6.46 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  208.   6.47 INDIA MARKET ANALYSIS BY GLUCAGON ORIGIN
  209.   6.48 INDIA MARKET ANALYSIS BY DOSAGE FORM
  210.   6.49 JAPAN MARKET ANALYSIS BY INDICATION
  211.   6.50 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  212.   6.51 JAPAN MARKET ANALYSIS BY GLUCAGON ORIGIN
  213.   6.52 JAPAN MARKET ANALYSIS BY DOSAGE FORM
  214.   6.53 SOUTH KOREA MARKET ANALYSIS BY INDICATION
  215.   6.54 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  216.   6.55 SOUTH KOREA MARKET ANALYSIS BY GLUCAGON ORIGIN
  217.   6.56 SOUTH KOREA MARKET ANALYSIS BY DOSAGE FORM
  218.   6.57 MALAYSIA MARKET ANALYSIS BY INDICATION
  219.   6.58 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  220.   6.59 MALAYSIA MARKET ANALYSIS BY GLUCAGON ORIGIN
  221.   6.60 MALAYSIA MARKET ANALYSIS BY DOSAGE FORM
  222.   6.61 THAILAND MARKET ANALYSIS BY INDICATION
  223.   6.62 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  224.   6.63 THAILAND MARKET ANALYSIS BY GLUCAGON ORIGIN
  225.   6.64 THAILAND MARKET ANALYSIS BY DOSAGE FORM
  226.   6.65 INDONESIA MARKET ANALYSIS BY INDICATION
  227.   6.66 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  228.   6.67 INDONESIA MARKET ANALYSIS BY GLUCAGON ORIGIN
  229.   6.68 INDONESIA MARKET ANALYSIS BY DOSAGE FORM
  230.   6.69 REST OF APAC MARKET ANALYSIS BY INDICATION
  231.   6.70 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  232.   6.71 REST OF APAC MARKET ANALYSIS BY GLUCAGON ORIGIN
  233.   6.72 REST OF APAC MARKET ANALYSIS BY DOSAGE FORM
  234.   6.73 SOUTH AMERICA MARKET ANALYSIS
  235.   6.74 BRAZIL MARKET ANALYSIS BY INDICATION
  236.   6.75 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  237.   6.76 BRAZIL MARKET ANALYSIS BY GLUCAGON ORIGIN
  238.   6.77 BRAZIL MARKET ANALYSIS BY DOSAGE FORM
  239.   6.78 MEXICO MARKET ANALYSIS BY INDICATION
  240.   6.79 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  241.   6.80 MEXICO MARKET ANALYSIS BY GLUCAGON ORIGIN
  242.   6.81 MEXICO MARKET ANALYSIS BY DOSAGE FORM
  243.   6.82 ARGENTINA MARKET ANALYSIS BY INDICATION
  244.   6.83 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  245.   6.84 ARGENTINA MARKET ANALYSIS BY GLUCAGON ORIGIN
  246.   6.85 ARGENTINA MARKET ANALYSIS BY DOSAGE FORM
  247.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
  248.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  249.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY GLUCAGON ORIGIN
  250.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DOSAGE FORM
  251.   6.90 MEA MARKET ANALYSIS
  252.   6.91 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
  253.   6.92 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  254.   6.93 GCC COUNTRIES MARKET ANALYSIS BY GLUCAGON ORIGIN
  255.   6.94 GCC COUNTRIES MARKET ANALYSIS BY DOSAGE FORM
  256.   6.95 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
  257.   6.96 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  258.   6.97 SOUTH AFRICA MARKET ANALYSIS BY GLUCAGON ORIGIN
  259.   6.98 SOUTH AFRICA MARKET ANALYSIS BY DOSAGE FORM
  260.   6.99 REST OF MEA MARKET ANALYSIS BY INDICATION
  261.   6.100 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  262.   6.101 REST OF MEA MARKET ANALYSIS BY GLUCAGON ORIGIN
  263.   6.102 REST OF MEA MARKET ANALYSIS BY DOSAGE FORM
  264.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  265.   6.104 RESEARCH PROCESS OF MRFR
  266.   6.105 DRO ANALYSIS OF HEALTHCARE
  267.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  268.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  269.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  270.   6.109 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
  271.   6.110 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
  272.   6.111 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  273.   6.112 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
  274.   6.113 HEALTHCARE, BY GLUCAGON ORIGIN, 2024 (% SHARE)
  275.   6.114 HEALTHCARE, BY GLUCAGON ORIGIN, 2024 TO 2035 (USD Billion)
  276.   6.115 HEALTHCARE, BY DOSAGE FORM, 2024 (% SHARE)
  277.   6.116 HEALTHCARE, BY DOSAGE FORM, 2024 TO 2035 (USD Billion)
  278.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  279. 7 LIST OF TABLES
  280.   7.1 LIST OF ASSUMPTIONS
  281.     7.1.1
  282.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  283.     7.2.1 BY INDICATION, 2025-2035 (USD Billion)
  284.     7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  285.     7.2.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  286.     7.2.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  287.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  288.     7.3.1 BY INDICATION, 2025-2035 (USD Billion)
  289.     7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  290.     7.3.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  291.     7.3.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  292.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  293.     7.4.1 BY INDICATION, 2025-2035 (USD Billion)
  294.     7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  295.     7.4.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  296.     7.4.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  297.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  298.     7.5.1 BY INDICATION, 2025-2035 (USD Billion)
  299.     7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  300.     7.5.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  301.     7.5.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  302.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  303.     7.6.1 BY INDICATION, 2025-2035 (USD Billion)
  304.     7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  305.     7.6.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  306.     7.6.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  307.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  308.     7.7.1 BY INDICATION, 2025-2035 (USD Billion)
  309.     7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  310.     7.7.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  311.     7.7.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  312.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  313.     7.8.1 BY INDICATION, 2025-2035 (USD Billion)
  314.     7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  315.     7.8.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  316.     7.8.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  317.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  318.     7.9.1 BY INDICATION, 2025-2035 (USD Billion)
  319.     7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  320.     7.9.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  321.     7.9.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  322.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  323.     7.10.1 BY INDICATION, 2025-2035 (USD Billion)
  324.     7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  325.     7.10.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  326.     7.10.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  327.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  328.     7.11.1 BY INDICATION, 2025-2035 (USD Billion)
  329.     7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  330.     7.11.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  331.     7.11.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  332.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  333.     7.12.1 BY INDICATION, 2025-2035 (USD Billion)
  334.     7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  335.     7.12.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  336.     7.12.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  337.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  338.     7.13.1 BY INDICATION, 2025-2035 (USD Billion)
  339.     7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  340.     7.13.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  341.     7.13.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  342.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  343.     7.14.1 BY INDICATION, 2025-2035 (USD Billion)
  344.     7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  345.     7.14.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  346.     7.14.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  347.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  348.     7.15.1 BY INDICATION, 2025-2035 (USD Billion)
  349.     7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  350.     7.15.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  351.     7.15.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  352.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  353.     7.16.1 BY INDICATION, 2025-2035 (USD Billion)
  354.     7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  355.     7.16.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  356.     7.16.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  357.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  358.     7.17.1 BY INDICATION, 2025-2035 (USD Billion)
  359.     7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  360.     7.17.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  361.     7.17.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  362.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  363.     7.18.1 BY INDICATION, 2025-2035 (USD Billion)
  364.     7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  365.     7.18.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  366.     7.18.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  367.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  368.     7.19.1 BY INDICATION, 2025-2035 (USD Billion)
  369.     7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  370.     7.19.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  371.     7.19.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  372.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  373.     7.20.1 BY INDICATION, 2025-2035 (USD Billion)
  374.     7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  375.     7.20.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  376.     7.20.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  377.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  378.     7.21.1 BY INDICATION, 2025-2035 (USD Billion)
  379.     7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  380.     7.21.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  381.     7.21.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  382.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  383.     7.22.1 BY INDICATION, 2025-2035 (USD Billion)
  384.     7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  385.     7.22.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  386.     7.22.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  387.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  388.     7.23.1 BY INDICATION, 2025-2035 (USD Billion)
  389.     7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  390.     7.23.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  391.     7.23.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  392.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  393.     7.24.1 BY INDICATION, 2025-2035 (USD Billion)
  394.     7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  395.     7.24.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  396.     7.24.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  397.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  398.     7.25.1 BY INDICATION, 2025-2035 (USD Billion)
  399.     7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  400.     7.25.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  401.     7.25.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  402.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  403.     7.26.1 BY INDICATION, 2025-2035 (USD Billion)
  404.     7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  405.     7.26.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  406.     7.26.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  407.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  408.     7.27.1 BY INDICATION, 2025-2035 (USD Billion)
  409.     7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  410.     7.27.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  411.     7.27.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  412.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  413.     7.28.1 BY INDICATION, 2025-2035 (USD Billion)
  414.     7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  415.     7.28.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  416.     7.28.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  417.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  418.     7.29.1 BY INDICATION, 2025-2035 (USD Billion)
  419.     7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  420.     7.29.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  421.     7.29.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  422.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  423.     7.30.1 BY INDICATION, 2025-2035 (USD Billion)
  424.     7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  425.     7.30.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  426.     7.30.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
  427.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  428.     7.31.1
  429.   7.32 ACQUISITION/PARTNERSHIP
  430.     7.32.1

Healthcare Market Segmentation

Healthcare By Indication (USD Billion, 2025-2035)

  • Hypoglycemia
  • Diabetic Ketoacidosis
  • Other Indications

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Intravenous
  • Subcutaneous
  • Intramuscular

Healthcare By Glucagon Origin (USD Billion, 2025-2035)

  • Human
  • Synthetic
  • Animal-derived

Healthcare By Dosage Form (USD Billion, 2025-2035)

  • Injectable
  • Nasal Spray
  • Other Dosage Forms

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions